Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L transcription

Blood

Volumn 117, Issue 14, 2011, Pages 3826-3835

  Wang, Yang ^a,b   Su, Mingwan ^b,c   Zhou, Liang L ^d   Tu, Ping ^a   Zhang, Xuejun ^e   Jiang, Xiaoyan ^b,d   Zhou, Youwen ^b,c,e  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CD4 ANTIGEN; CD7 ANTIGEN; FAS LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FASL GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; RETROVIRUS; SATB1 GENE; SEZARY CELL; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 79953833243     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294819     Document Type: Article

References (49)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768-3785. (Pubitemid 40656118)
2. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T-cell lymphoma. J Exp Med. 2003; 197(11): 1477-1488. (Pubitemid 36682545)
3. Rappl G, Muche JM, Abken H, et al. CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sezary syndrome. J AmAcad Dermatol. 2001; 44(3): 456-461. (Pubitemid 32199965)
4. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. Clin Exp Dermatol. 2005; 30(6): 702-706. (Pubitemid 41499832)
5. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sezary syndrome. Lancet. 2008; 371(9616): 945-957.
6. Klemke CD, Brenner D, Weiss EM, et al. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res. 2009; 69(10): 4175-4183.
7. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007; 7(7): 532-542. (Pubitemid 46987784)
8. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003; 193: 70-81. (Pubitemid 36688041)
9. Wasco MJ, Fullen D, Su L, Ma L. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders. Hum Pathol. 2008; 39(4): 557-563.
10. Mao X, Orchard G, Mitchell TJ, et al. A genomic and expression study of AP-1 in primary cutaneous T-cell lymphoma: evidence for dysregulated expression of JUNB and JUND in MF and SS. J Cutan Pathol. 2008; 35(10): 899-910.
11. Booken N, Gratchev A, Utikal J, et al. Sezary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia. 2008; 22(2): 393-399. (Pubitemid 351250545)
12. Hahtola S, Tuomela S, Elo L, et al. Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma. Clin Cancer Res. 2006; 12(16): 4812-4821. (Pubitemid 44338565)
13. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker SJ. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood. 2003; 101(4): 1513-1519. (Pubitemid 36182528)
14. Ringrose A, Zhou Y, Pang E, et al. Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas. Leukemia. 2006; 20(9): 1593-1601. (Pubitemid 44264103)
15. Su MW, Dorocicz I, Dragowska WH, et al. Aberrant expression of T-plastin in Sezary cells. Cancer Res. 2003; 63(21): 7122-7127. (Pubitemid 37413449)
16. Kennah E, Ringrose A, Zhou LL, et al. Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells. Blood. 2009; 113(19): 4646-4655.
17. Mao X, McElwaine S. Functional copy number changes in Sezary syndrome: toward an integrated molecular cytogenetic map III. Cancer Genet Cytogenet. 2008; 185(2): 86-94.
18. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002; 46(1):95-106. (Pubitemid 34073484)
19. Zhou LL, Zhao Y, Ringrose A, et al. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med. 2008; 205(11): 2657-2671.
20. Jiang X, Ng E, Yip C, et al. Primitive interleukin 3 null hematopoietic cells transduced with BCRABL show accelerated loss after culture of factorindependence in vitro and leukemogenic activity in vivo. Blood. 2002; 100(10): 3731-3740. (Pubitemid 35303945)
21. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 1991; 353(6347): 858-861. (Pubitemid 21912642)
22. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002; 8(5): 1234-1240. (Pubitemid 34517663)
23. van Doorn R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res. 2004; 64(16): 5578-5586. (Pubitemid 39095552)
24. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res. 2010;38(Database issue):D682-D689.
25. Kim J, Hong SJ, Park JY, et al. Epithelialmesenchymal transition gene signature to predict clinical outcome of hepatocellular carcinoma. Cancer Sci. 2010; 101(6): 1521-1528.
26. Bruland O, Fluge O, Akslen LA, et al. Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer. 2009;9:425.
27. Rossetti S, Hoogeveen AT, Esposito J, Sacchi N. Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis. J Cell Mol Med. 2009;14(6A):1358-1370.
28. Li FJ, Ding S, Pan J, et al. FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood. 2008; 112(1): 179-187.
29. Krasnov GS, Oparina N, Khankin SL, et al. [Colorectal cancer 2D-proteomics: identification of altered protein expression]. Mol Biol (Mosk). 2009; 43(2): 348-356.
30. Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002; 419(6907): 641-645.
31. Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet. 2006; 38(11): 1278-1288. (Pubitemid 44646290)
32. Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000; 14(5): 521-535. (Pubitemid 30159772)
33. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992; 70(4): 631-645.
34. Cai S, Han HJ, Kohwi-Shigematsu T. Tissuespecific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34(1):42-51. (Pubitemid 36548789)
35. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008; 452(7184): 187-193. (Pubitemid 351380252)
36. Lechner O, Lauber J, Franzke A, Sarukhan A, von Boehmer H, Buer J. Fingerprints of anergic T cells. Curr Biol. 2001; 11(8): 587-595. (Pubitemid 32324761)
37. Matsumoto Y, Oshida T, Obayashi I, et al. Identification of highly expressed genes in peripheral blood T cells from patients with atopic dermatitis. Int Arch Allergy Immunol. 2002; 129(4): 327-340.
38. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol. 1992; 99(1): 90-94.
39. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009; 129(5): 1165-1173.
40. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol. 1995; 22(1): 11-17.
41. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145(6): 928-937. (Pubitemid 34204467)
42. Kuzel TM. Systemic chemotherapy for the treatment of mycosis fungoides and Sezary syndrome. Dermatol Ther. 2003; 16(4): 355-361. (Pubitemid 38044680)
43. Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol. 2009; 129(5): 1059-1061.
44. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T-cell lymphomas. J Invest Dermatol. 2005; 124(4): 741-750. (Pubitemid 40489501)
45. Braun FK, Fecker LF, Schwarz C, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007; 127(10): 2425-2437. (Pubitemid 47619746)
46. Contassot E, Kerl K, Roques S, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood. 2008; 111(9): 4780-4787.
47. Baumann S, Dostert A, Novac N, et al. Glucocorticoids inhibit activation-induced cell death (AICD) via direct DNA-dependent repression of the CD95 ligand gene by a glucocorticoid receptor dimer. Blood. 2005; 106(2): 617-625. (Pubitemid 40981259)
48. Bladon J, Taylor PC. Treatment of cutaneous Tcell lymphoma with extracorporeal photopheresis induces Fas-ligand expression on treated T cells, but does not suppress the expression of costimulatory molecules on monocytes. J Photochem Photobiol B. 2003; 69(2): 129-138. (Pubitemid 36336468)
49. Renno T, Hahne M, Tschopp J, MacDonald HR. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med. 1996; 183(2): 431-437. (Pubitemid 26059508)